SG10202109654SA - HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY - Google Patents
HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPYInfo
- Publication number
- SG10202109654SA SG10202109654SA SG10202109654SA SG10202109654SA SG 10202109654S A SG10202109654S A SG 10202109654SA SG 10202109654S A SG10202109654S A SG 10202109654SA SG 10202109654S A SG10202109654S A SG 10202109654SA
- Authority
- SG
- Singapore
- Prior art keywords
- adcs
- therapy
- drug conjugates
- antibody drug
- hdac inhibitors
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 2
- 229940049595 antibody-drug conjugate Drugs 0.000 title 2
- 102000003964 Histone deacetylase Human genes 0.000 title 1
- 108090000353 Histone deacetylase Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163065.0A EP3381474A1 (en) | 2017-03-27 | 2017-03-27 | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202109654SA true SG10202109654SA (en) | 2021-10-28 |
Family
ID=58448395
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202109654S SG10202109654SA (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
SG11201906543RA SG11201906543RA (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906543RA SG11201906543RA (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210128740A1 (en) |
EP (2) | EP3381474A1 (en) |
JP (1) | JP2020515578A (en) |
KR (1) | KR20190126824A (en) |
CN (1) | CN110475572A (en) |
AU (1) | AU2018241840A1 (en) |
BR (1) | BR112019013449A2 (en) |
CA (1) | CA3047359A1 (en) |
EA (1) | EA201991985A1 (en) |
IL (1) | IL268821A (en) |
MX (1) | MX2019011492A (en) |
SG (2) | SG10202109654SA (en) |
TN (1) | TN2019000187A1 (en) |
UA (1) | UA125311C2 (en) |
WO (1) | WO2018178060A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020176513A1 (en) * | 2019-02-25 | 2020-09-03 | Emory University | Chimeric compounds and methods of managing neurological disorders or conditions |
KR20230042057A (en) * | 2020-07-20 | 2023-03-27 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Sulfur-Containing Isoindoline Derivatives and Methods for Their Preparation and Medical Uses Thereof |
CN112430229B (en) * | 2020-11-24 | 2023-03-21 | 福建医科大学 | Compound for targeted degradation of PARP protein and preparation method and application thereof |
CN113292465B (en) * | 2021-06-17 | 2022-11-08 | 贵州医科大学 | Cysteine derivative and synthesis method and application thereof |
WO2023059581A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
WO2023061405A1 (en) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | Highly-stable targeted linker-drug conjugate |
CN118085013A (en) * | 2022-11-25 | 2024-05-28 | 成都微芯新域生物技术有限公司 | Connector, antibody drug conjugate containing connector, and preparation method and application of antibody drug conjugate |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045307A (en) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | Antibody-drug conjugates and method |
EP1957056A2 (en) * | 2005-11-10 | 2008-08-20 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
WO2009134976A1 (en) * | 2008-04-30 | 2009-11-05 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
AU2014286872B2 (en) * | 2013-07-05 | 2020-01-23 | Formation Biologics Inc. | EGFR antibody conjugates |
SI3129406T1 (en) * | 2014-04-11 | 2019-04-30 | Medimmune, Llc | Conjugated compounds comprising cysteine-engineered antibodies |
-
2017
- 2017-03-27 EP EP17163065.0A patent/EP3381474A1/en not_active Withdrawn
-
2018
- 2018-03-27 UA UAA201909898A patent/UA125311C2/en unknown
- 2018-03-27 MX MX2019011492A patent/MX2019011492A/en unknown
- 2018-03-27 EP EP18712246.0A patent/EP3600444A1/en not_active Withdrawn
- 2018-03-27 CN CN201880022128.4A patent/CN110475572A/en active Pending
- 2018-03-27 EA EA201991985A patent/EA201991985A1/en unknown
- 2018-03-27 US US16/492,355 patent/US20210128740A1/en not_active Abandoned
- 2018-03-27 SG SG10202109654S patent/SG10202109654SA/en unknown
- 2018-03-27 JP JP2019553113A patent/JP2020515578A/en active Pending
- 2018-03-27 KR KR1020197028286A patent/KR20190126824A/en not_active Application Discontinuation
- 2018-03-27 TN TNP/2019/000187A patent/TN2019000187A1/en unknown
- 2018-03-27 WO PCT/EP2018/057744 patent/WO2018178060A1/en unknown
- 2018-03-27 SG SG11201906543RA patent/SG11201906543RA/en unknown
- 2018-03-27 BR BR112019013449A patent/BR112019013449A2/en not_active IP Right Cessation
- 2018-03-27 AU AU2018241840A patent/AU2018241840A1/en active Pending
- 2018-03-27 CA CA3047359A patent/CA3047359A1/en active Pending
-
2019
- 2019-08-21 IL IL26882119A patent/IL268821A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018241840A1 (en) | 2019-10-03 |
EA201991985A1 (en) | 2020-02-25 |
TN2019000187A1 (en) | 2020-10-05 |
US20210128740A1 (en) | 2021-05-06 |
CN110475572A (en) | 2019-11-19 |
WO2018178060A1 (en) | 2018-10-04 |
UA125311C2 (en) | 2022-02-16 |
BR112019013449A2 (en) | 2019-12-31 |
CA3047359A1 (en) | 2018-10-04 |
EP3600444A1 (en) | 2020-02-05 |
JP2020515578A (en) | 2020-05-28 |
IL268821A (en) | 2019-10-31 |
EP3381474A1 (en) | 2018-10-03 |
KR20190126824A (en) | 2019-11-12 |
SG11201906543RA (en) | 2019-08-27 |
MX2019011492A (en) | 2019-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202003833B (en) | Conjugates and preparation and use thereof | |
IL304717A (en) | Anti-cmet antibody drug conjugates and methods their use | |
IL268821A (en) | Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy | |
IL265309A (en) | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates | |
CY1121907T1 (en) | ANTIDLL3-ANTISOMATO-PBD CONJUGATES AND USES THEREOF | |
HK1259127A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
IL268206A (en) | Bcma-targeting antibody and use thereof | |
IL279015A (en) | Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof | |
HK1257056A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
IL282292A (en) | Fc silenced antibody drug conjugates (adcs) and uses thereof | |
IL286483A (en) | Claudin-6 antibodies and drug conjugates | |
GB201604213D0 (en) | Drug combination and its use in therapy | |
SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
PT3544637T (en) | Nomv-antigen conjugates and use thereof | |
ZA201906248B (en) | Anti-ceacam1 antibody and use thereof | |
IL265645A (en) | Cmet monoclonal binding agents, drug conjugates thereof and uses thereof | |
IL272920A (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
SG11202003585VA (en) | Anti-vista antibody and use thereof | |
SG11202011576VA (en) | Anti-sez6 antibody drug conjugates and methods of use | |
EP3675908A4 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
EP3647325A4 (en) | Pharmaceutical composition comprising pcsk-9 antibody and use thereof | |
PL3630188T3 (en) | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | |
IL292646A (en) | Pharmaceutical combination and use thereof | |
GB201712101D0 (en) | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | |
GB201818562D0 (en) | Pyrrolobenzodiazephones and conjugates thereof |